As of 2026-04-06, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -6.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 922.15 mil USD. URGN's TTM EBITDA according to its financial statements is -143.73 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 11.2x | 10.7x |
| Forward P/E multiples | 9.0x - 11.7x | 11.2x |
| Fair Price | (26.79) - (33.28) | (32.66) |
| Upside | -243.9% - -278.8% | -275.5% |
| Date | EV/EBITDA |
| 2026-04-06 | -6.42 |
| 2026-04-02 | -6.49 |
| 2026-04-01 | -6.53 |
| 2026-03-31 | -6.20 |
| 2026-03-30 | -5.87 |
| 2026-03-27 | -5.93 |
| 2026-03-26 | -6.18 |
| 2026-03-25 | -6.25 |
| 2026-03-24 | -6.09 |
| 2026-03-23 | -5.97 |
| 2026-03-20 | -6.08 |
| 2026-03-19 | -6.41 |
| 2026-03-18 | -6.37 |
| 2026-03-17 | -6.41 |
| 2026-03-16 | -6.46 |
| 2026-03-13 | -6.36 |
| 2026-03-12 | -6.48 |
| 2026-03-11 | -6.49 |
| 2026-03-10 | -6.70 |
| 2026-03-09 | -6.86 |
| 2026-03-06 | -7.04 |
| 2026-03-05 | -6.75 |
| 2026-03-04 | -6.94 |
| 2026-03-03 | -6.49 |
| 2026-03-02 | -6.55 |
| 2026-02-27 | -7.46 |
| 2026-02-26 | -7.29 |
| 2026-02-25 | -7.11 |
| 2026-02-24 | -7.14 |
| 2026-02-23 | -7.20 |
| 2026-02-20 | -7.25 |
| 2026-02-19 | -7.50 |
| 2026-02-18 | -7.66 |
| 2026-02-17 | -7.09 |
| 2026-02-13 | -6.92 |
| 2026-02-12 | -6.96 |
| 2026-02-11 | -7.27 |
| 2026-02-10 | -7.45 |
| 2026-02-09 | -7.53 |
| 2026-02-06 | -7.34 |
| 2026-02-05 | -7.06 |
| 2026-02-04 | -7.13 |
| 2026-02-03 | -6.89 |
| 2026-02-02 | -6.79 |
| 2026-01-30 | -6.75 |
| 2026-01-29 | -7.12 |
| 2026-01-28 | -7.33 |
| 2026-01-27 | -7.51 |
| 2026-01-26 | -7.25 |
| 2026-01-23 | -6.89 |